Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Atrial Fibrillation
Scientists at University of Montreal target atrial fibrillation
May 12th, 2008
"The present study assessed the efficacy and safety of vernakalant hydrochloride ( RSD1235), a novel compound, for the conversion of atrial fibrillation ( AF). Patients were randomized in a 2:1 ratio to receive vernakalant or placebo and were stratified by AF duration of 3 hours to 7 days ( short duration) and 8 to 45 days ( long duration)," scientists writing in the journal Circulation report. "A first infusion of placebo or vernakalant ( 3 mg/kg) was given for 10 minutes, followed by a second infusion of placebo or vernakalant ( 2 mg/kg) 15 minutes later if AF was not terminated. The primary end point was conversion of AF to sinus rhythm for at least 1 minute...
Source: Biotech Business Week (2008-05-12)
|
